News & Updates
Filter by Specialty:
Apremilast safe, effective in moderate-to-severe genital psoriasis
Treatment with apremilast demonstrates consistent efficacy in genital psoriasis and overall psoriasis symptoms at 16 weeks irrespective of body surface area (BSA) at baseline, suggest the results of the phase III DISCREET trial presented at the recent AAD 2023.
Apremilast safe, effective in moderate-to-severe genital psoriasis
13 Apr 2023
Mirabegron may improve sexual function in adults with OAB
Mirabegron, a ß3 adrenoceptor agonist, delivers benefit for both men and women with overactive bladder (OAB) who are experiencing sexual dysfunction, a systematic review and meta-analysis reports.
Mirabegron may improve sexual function in adults with OAB
13 Apr 2023
Lebrikizumab helps clear skin of teens with moderate-to-severe atopic dermatitis
Treatment with lebrikizumab with or without topical corticosteroids (TCS) results in clinical improvement among adolescents with moderate-to-severe atopic dermatitis (AD), according to a study presented at the recent AAD 2023.
Lebrikizumab helps clear skin of teens with moderate-to-severe atopic dermatitis
12 Apr 2023
Ripretinib improves survival in advanced gastrointestinal stromal tumours
Treatment with ripretinib provides a prolonged clinical and radiological benefit in patients with advanced gastrointestinal stromal tumours (GIST) within the expanded access program (EAP) in the UK, as shown in a study presented at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.